PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsNewsRat's vision restored with stem cell treatment

BioNews

Rat's vision restored with stem cell treatment

Published 13 February 2013 posted in News and appears in BioNews 648

Author

Dr Nadeem Shaikh

Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
CC BY 4.0
Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.

A potential stem cell therapy for glaucoma — a degenerative eye condition that can lead to blindness — has yielded positive results in animal tests...

A potential stem cell therapy for glaucoma — a degenerative eye condition that can lead to blindness — has yielded positive results in animal tests. The treatment led to a 50 percent improvement in vision in rats with a model of the disease.

Glaucoma is a condition where pressure builds up in the eye, resulting in the death of retinal ganglion cells (RGCs) that normally form optic nerve fibres and help transmit information from the eye to the brain. It affects about 500,000 people in the UK, and 70 million people across the world. One in ten people with the disease go blind, often either because they were diagnosed too late or because their condition was too severe to be treated. In such cases, there is currently no way to reverse the blindness.

In this study, scientists at University College London, and Moorfields Eye Hospital, used adult stem cells called Müller glia cells. These rare cells, in this case isolated from corneas from organ donors, are multipotent, meaning they can develop into any type of eye cell. The scientists induced the Müller glia cells to develop into precursors to RGCs, then placed them in rats whose RGCs had been damaged in a way to simulate glaucoma. After four weeks the cells had not merged with the afflicted rat cell population but instead formed new bridges between undamaged sections. Under very low light conditions, the rats' vision had improved by 50 percent.

Dr Astrid Limb of the UCL Institute of Ophthalmology, and leader of the research team, said: 'Although this research is still a long way from the clinic, it is a significant step towards our ultimate goal of finding a cure for glaucoma and other related conditions. We are optimistic that [...] we will be in a good position to start early-stage clinical trials on humans in around three to five years'.

Dr Rob Buckle, head of regenerative medicine at the Medical Research Council (MRC), which funded the research, said: 'Regenerative medicine is a key priority for the MRC and it's wonderful to see another example of how our significant investment in stem cell research in recent years is beginning to deliver results. Repair of the eye is an area that is now at the forefront of this field, and this study highlights a new route for delivering the promise of regenerative medicine to treat disabling conditions such as glaucoma'.

Other groups are also using stem cell technology to treat ocular diseases. The US company, Advanced Cell Technology, received the go-ahead earlier this year for a clinical trial to test a proposed stem cell therapy for advanced Stargardt disease — a leading cause of blindness in young people (reported in BioNews 642). That trial, which will be conducted in partnership with Moorfields Eye Hospital, will use human embryonic — rather than adult — stem cells.

Related Articles

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).
News
6 October 2014 • 2 minutes read

Readily accessible eye stem cells could be used to treat blindness

by Dr Greg Ball

A pool of stem cells found on the surface of the eye can be used to form light-sensitive cells that could one day treat blindness, researchers have reported...

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).
News
13 June 2014 • 2 minutes read

Light-sensing retina created using stem cells

by Alice Plein

In a research first, a section of light-sensing tissue, closely resembling the human retina, has been grown in the laboratory from human stem cells...

Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
CC BY 4.0
Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
News
25 July 2013 • 2 minutes read

Lab-made retina cells functional in mice

by Dr Greg Ball

Light-sensitive cells found in the retina have been grown from mouse embryonic stem cells (ESCs) and successfully transplanted into the eyes of visually impaired mice, restoring some vision...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
17 June 2013 • 2 minutes read

The eyes have it: gene therapy delivered to retina in mice

by Rhys Baker

A 'non-invasive' method for delivering gene therapy into the eye has been developed by US researchers...

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).
News
28 February 2013 • 1 minute read

First patients receive eye stem cell transplants in attempt to restore sight

by Ana Pallesen

Two patients with corneal blindness have become the first people in the UK to have stem cells transplanted into their eyes in order to restore their sight...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
30 January 2013 • 2 minutes read

Gene therapy successfully treats inherited blindness

by Dr Maria Botcharova

Three women have reported a significant improvement in sight following gene therapy in both their eyes. Initially, they received the therapy in just one eye, but this latest study demonstrates the treatment was also successful in the other...

Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false colour).
CC BY 4.0
Image by Sílvia Ferreira, Cristina Lopo and Eileen Gentleman via the Wellcome Collection. Depicts a single human stem cell embedded within a porous hydrogel matrix (false-coloured cryogenic scanning electron micrograph).
News
30 January 2013 • 1 minute read

US stem cell company given green light for blindness trials

by Ruth Retassie

US company StemCells Inc have received Food and Drug Administration (FDA) authorisation to carry out clinical trials of their treatment for one of the leading causes of blindness in over 55-year-olds...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Comment
30 January 2013 • 3 minutes read

With an eye to the future - preliminary results of clinical trial in human embryonic stem cell-based therapy of macular degeneration

by Dr Dusko Ilic and 1 others

Last week, Advanced Cell Technology (ACT) of Massachusetts, USA, made two important announcements regarding human embryonic stem (hES) cell-based therapies for the potential treatment of Stargardt's dystrophy and age-related macular degeneration, two devastating degenerative disease leading to blindness....

Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
CC BY 4.0
Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
News
30 January 2013 • 2 minutes read

Stem cell transplants hold hope for treating blindness

by Rosemary Paxman

A clinical trial testing the safety of using human embryonic stem cell (hESC) in the treatment of progressive eye conditions has been carried out by researchers in the USA...

Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
CC BY 4.0
Image by K Hardy via the Wellcome Collection. Depicts a human embryo at the blastocyst stage (about six days after fertilisation) 'hatching' out of the zona pellucida.
News
17 October 2012 • 1 minute read

Stem cell therapy used to treat glaucoma in rats

by Dr Lux Fatimathas

UK scientists have shown stem cells can be used to successfully stop glaucoma, an eye disorder, in rats. Stem cells were isolated from bone marrow and successfully grafted onto damaged nerves in the eye...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Stem cell treatment counters kidney rejection in early trial

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
8 August 2022 • 2 minutes read

Placenta and organ formation observed in mouse embryo models

8 August 2022 • 2 minutes read

Lower hormone doses may improve IVF egg quality

8 August 2022 • 2 minutes read

Boosting muscle cell production of gene therapy proteins

1 August 2022 • 2 minutes read

First UK medical guidelines issued for trans fertility preservation

1 August 2022 • 2 minutes read

Male age has more impact on IVF birth rate than previously thought

15 August 2022 • 2 minutes read

Call to end ban on HIV-positive partner gamete 'donation'

15 August 2022 • 2 minutes read

Melanoma invades new tissues using nerve cell gene

15 August 2022 • 2 minutes read

Exceeding alcohol limits could damage DNA and accelerate ageing

15 August 2022 • 2 minutes read

Blood cell gene mutations affect mitochondria, increasing cardiovascular disease risk

15 August 2022 • 2 minutes read

Jumping gene helps immune system fight viruses

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856